Research Advances in Tumor-targeting Bacteria <i>Escherichia coli</i> Nissle 1917 in Cancer Therapy

doi:10.13523/j.cb.2301036

China Biotechnology

2023, Vol. 43

Issue (6): 54-68 DOI: 10.13523/j.cb.2301036

Research Advances in Tumor-targeting Bacteria Escherichia coli Nissle 1917 in Cancer Therapy

LI Yu-tong,CUI Tian-qi,ZHANG Hai-lin,YU Guang-le,LUAN Ji^**(

),WANG Hai-long^**(

)

State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao 266237, China

Download:

HTML

PDF(1483KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Traditional cancer therapies such as chemotherapy and radiotherapy have problems such as poor targeting and high toxic side effects. Tumor-targeting bacteria can specifically colonize in the solid tumor microenvironment, and can be genetically engineered to synthesize anti-cancer drugs, improve the selectivity of drugs for tumor tissues and avoid the damage to normal tissues by chemotherapeutic drugs. These advantages make tumor-targeting bacteria a research hot spot in targeted cancer therapy in recent years. Escherichia coli Nissle 1917(EcN), a probiotic bacterium that has been widely studied and used, has attracted much attention in bacterial cancer therapies. EcN is non-pathogenic and non-immunotoxic and has a highly effective tumor-targeting ability. It can be rapidly cleared in normal tissues. Here, the latest advances in engineering of EcN for tumor-targeting therapy were reviewed. The applications of EcN in adjuvant therapy were also discussed. With the advancement of genetic engineering and synthetic biology, scientists’ ability to design and synthesize bacteria is growing stronger. EcN as a programmable living drug holds the promise of becoming a powerful weapon against cancer.

Key words： Bacteriotherapy Tumor-targeting therapy Cancer Synthetic biology Escherichia coli Nissle 1917

Received: 27 January 2023 Published: 04 July 2023

ZTFLH:

Q819

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Yu-tong LI
	Tian-qi CUI
	Hai-lin ZHANG
	Guang-le YU
	Ji LUAN
	Hai-long WANG

Cite this article:

LI Yu-tong, CUI Tian-qi, ZHANG Hai-lin, YU Guang-le, LUAN Ji, WANG Hai-long. Research Advances in Tumor-targeting Bacteria Escherichia coli Nissle 1917 in Cancer Therapy. China Biotechnology, 2023, 43(6): 54-68.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2301036 OR https://manu60.magtech.com.cn/biotech/Y2023/V43/I6/54

菌株	作用方式	机制	肿瘤类型	参考文献
S. typhimurium ΔppGpp	提高安全性	敲除relA和spoT基因,阻断ppGpp的合成	-	[9]
L. monocytogenes ΔactA/ΔinlB	提高安全性	敲除毒力基因actA和inlB	CT26小鼠结肠癌	[10]
E. coli Nissle 1917	提高安全性	通过调节kifC基因表达水平来动态调节细菌表面荚膜多糖的生成	4T1小鼠乳腺癌,CT26小鼠结肠癌	[11]
S. typhimurium SL1344	提高安全性	整合同步裂解回路	MC26小鼠结肠癌	[12]
S. typhimurium A1	提高靶向性	Leu和Arg营养缺陷型	PC-3人前列腺癌	[13]
S. typhimurium SF104	提高靶向性	aroA基因突变,芳香族氨基酸营养缺陷型	CT26小鼠结肠癌,Renca小鼠肾癌	[14]
E. coli Nissle 1917	提高靶向性	胸苷和DAP营养缺陷型	B16-F10小鼠黑色素瘤,EL4小鼠胸腺淋巴瘤,A20小鼠B细胞淋巴瘤,4T1小鼠乳腺癌,CT26小鼠结肠癌	[15]
S. typhimurium YB1	提高靶向性	将调节DAP合成的asd基因置于缺氧诱导的启动子下	MDA-MB-231人乳腺癌	[16]
S. typhimurium VNP20009	提高靶向性	表达癌胚抗原(CEA)特异性抗体	MC38小鼠结肠癌	[17]
S. typhimurium ΔppGpp	提高靶向性	将RGD序列融合在细菌外膜蛋白A上,以靶向癌细胞表面高表达的整合素αvβ3	MDA-MB-231人乳腺癌,MDA-MB-435人黑色素瘤,U87MG人胶质母细胞瘤,MCF7人乳腺癌,ASPC-1人胰腺癌,CT26小鼠结肠癌,4T1小鼠乳腺癌	[18]
S. typhimurium VNP20009	提高靶向性	在细菌表面偶联肿瘤特异性适配体	4T1小鼠乳腺癌,H22小鼠肝细胞癌	[19]
S. typhimurium VNP20009	提高安全性和靶向性	敲除msbB和purI基因,使LPS中的类脂A豆蔻酰化,嘌呤营养缺陷型	B16-F10小鼠黑色素瘤,LOX人黑色素瘤,DLD-1人结肠癌	[20]
S. typhimurium S636	提高安全性和靶向性	aroA基因突变以及参与类脂A修饰的其他突变	CT26小鼠结肠癌,B16-F10小鼠黑色素瘤	[21]
E. coli Nissle 1917	表达细胞毒性药物	产生生物丁酸盐,导致细胞周期在G₁期停滞,并诱导独立于p53的线粒体凋亡途径	HT29人结肠癌	[22]
E. coli Nissle 1917	表达细胞毒性药物	表达溶血素E,诱导细胞凋亡	HT29人结肠癌,SW620人结肠癌	[23]
S. typhimurium VNP20009	表达前药转化酶	表达羧肽酶G2,激活前药并在人肿瘤细胞中诱导细胞毒性	MDA-MB-361人乳腺癌,WiDr人结肠癌,B16-F10小鼠黑色素瘤	[24]
E. coli DH5α	表达前药转化酶	表达β-葡糖醛酸酶,将前药9ACG转化为9AC,增加化疗的敏感性	CL1-5人肺腺癌	[25]
E. coli Nissle 1917	表达前药转化酶	表达黑芥子酶,将硫代葡萄糖苷转化为具抗癌活性的萝卜硫素	HCT116人结肠癌,LoVo人结肠癌,AGS人胃腺癌,MCF7人乳腺癌,CT26小鼠结肠癌	[26]
S. typhimurium S636	抑制肿瘤血管生成	递送抗血管生成剂内皮抑素	CT26小鼠结肠癌,B16-F10小鼠黑色素瘤	[21]
E. coli Nissle 1917	抑制肿瘤血管生成/提高可控性	利用缺氧诱导启动子控制Tum-5表达	B16-F10小鼠黑色素瘤	[27]
E. coli Nissle 1917	递送化疗药物	使用酸不稳定接头将化疗药物DOX连接在细菌表面	4T1小鼠乳腺癌	[28]
S. typhimurium LT2	递送化疗药物	将装载DOX的纳米脂质体递送到肿瘤组织	4T1小鼠乳腺癌	[29]
S. typhimurium SHJ2037	递送化疗药物	将装载紫杉醇的脂质体递送到肿瘤组织	4T1小鼠乳腺癌	[30]
S. typhimurium BRD509	调节免疫微环境	表达重组IFN-γ,即IFN-γ融合到SipB的N端区域(残基1~160)	B16-F10小鼠黑色素瘤	[31]
S. typhimurium BRD509	调节免疫微环境	表达细胞因子LIGHT	CT26小鼠结肠癌,D2F2小鼠乳腺癌,LLC小鼠肺癌	[32]
S. typhimurium GIDIL2	调节免疫微环境	在厌氧诱导的启动子下控制表达细胞因子IL-2	B16-F1小鼠黑色素瘤	[33]
E. coli Nissle 1917	调节免疫微环境	使用同步裂解回路,表达并局部释放CD47纳米抗体	A20小鼠B细胞淋巴瘤,4T1小鼠乳腺癌,B16-F10小鼠黑色素瘤	[34]
E. coli Nissle 1917	调节免疫微环境	使用同步裂解回路,表达并局部释放PD-L1和CTLA-4纳米抗体	CT26小鼠结肠癌,A20小鼠B细胞淋巴瘤	[35]
E. coli Nissle 1917	调节免疫微环境	表达STING激动剂CDA,激活抗原呈递细胞和肿瘤抗原呈递	B16-F10小鼠黑色素瘤,EL4小鼠淋巴细胞瘤,A20小鼠B细胞淋巴瘤,4T1小鼠乳腺癌,CT26小鼠结肠癌	[15]
L. rhamnosus Probio-M9	调节免疫微环境	恢复被抗生素破坏的肠道微生物菌群,与PD-1阻断疗法协同作用	CT26小鼠结肠癌	[36]
L. monocytogenes	调节免疫微环境	通过递送破伤风类毒素重新激活先前存在的记忆T细胞以杀死肿瘤细胞	Panc-02小鼠胰腺癌细胞,4T1小鼠乳腺癌	[37]
S. typhimurium YB1	光热疗法	在YB1表面共价连接负载有吲哚菁绿的纳米颗粒INPs,将INPs递送到缺氧肿瘤核心后其光热效应可以杀死肿瘤细胞	MB49小鼠膀胱癌	[38]
E. coli MG1655	调节免疫微环境/光热疗法	通过细菌上修饰的生物矿化金纳米颗粒AuNPs的光热效应控制TNF-α在肿瘤部位表达	4T1小鼠乳腺癌	[39]
S. typhimurium VNP20009	调节免疫微环境/光热疗法	在细菌表面涂覆聚多巴胺,并局部接种含有PD-1的基于磷脂的相分离凝胶	B16-F10小鼠黑色素瘤	[40]
E. coli Nissle 1917	调节免疫微环境/光热疗法	在细菌表面偶联基于PDA纳米颗粒与OVA抗原和α-PD-1抗体的三重免疫纳米激活剂	CT26小鼠结肠癌,MC38小鼠结肠癌	[41]
E. coli BL21(DE3)	调节免疫微环境/光热疗法	表达产生黑色素,通过多巴胺的原位聚合将αPD-1锚定在细菌表面	4T1小鼠乳腺癌	[42]
Synechococcus 7942	光动力疗法	光敏剂附着在Syne表面,实现肿瘤靶向光敏剂递送和原位光催化制氧	4T1小鼠乳腺癌	[43]
E. coli MG1655	光动力疗法/ 递送化疗药物	通过仿生矿化在细菌上装载了含有光敏剂Ce6和化疗药物DOX的ZIF-8涂层	4T1小鼠乳腺癌	[44]

Table 1 Bacteria for the tumor-targeting therapy and their action mode

Fig.1 Three strategies to improve the controllability of EcN

Fig.2 Applications of EcN in adjuvant therapy of tumor


[1]	Yi C, Huang Y, Guo Z Y, et al. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacologica Sinica, 2005, 26(5): 629-634. doi: 10.1111/j.1745-7254.2005.00094.x

[2]	Van Mellaert L, Barbé S, Anné J. Clostridium spores as anti-tumour agents. Trends in Microbiology, 2006, 14(4): 190-196. pmid: 16500103

[3]	Thamm D, Kurzman I, King I, et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clinical Cancer Research, 2005, 11: 4827-4834. doi: 10.1158/1078-0432.CCR-04-2510

[4]	Stritzker J, Weibel S, Hill P J, et al. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. International Journal of Medical Microbiology, 2007, 297(3): 151-162. doi: 10.1016/j.ijmm.2007.01.008

[5]	Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science, 2020, 368(6494): 973-980. doi: 10.1126/science.aay9189 pmid: 32467386

[6]	Sepich-Poore G D, Zitvogel L, Straussman R, et al. The microbiome and human cancer. Science, 2021, 371(6536): eabc4552. doi: 10.1126/science.abc4552

[7]	Poore G D, Kopylova E, Zhu Q Y, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature, 2020, 579(7800): 567-574. doi: 10.1038/s41586-020-2095-1

[8]	Kramer M G, Masner M, Ferreira F A, et al. Bacterial therapy of cancer: promises, limitations, and insights for future directions. Frontiers in Microbiology, 2018, 9: 16. doi: 10.3389/fmicb.2018.00016 pmid: 29472896

[9]	Na H S, Kim H J, Lee H C, et al. Immune response induced by Salmonella typhimurium defective in ppGpp synthesis. Vaccine, 2006, 24(12): 2027-2034. doi: 10.1016/j.vaccine.2005.11.031

[10]	Brockstedt D G, Giedlin M A, Leong M L, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(38): 13832-13837.

[11]	Harimoto T, Hahn J, Chen Y Y, et al. A programmable encapsulation system improves delivery of therapeutic bacteria in mice. Nature Biotechnology, 2022, 40(8): 1259-1269. doi: 10.1038/s41587-022-01244-y pmid: 35301496

[12]	Din M O, Danino T, Prindle A, et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature, 2016, 536(7614): 81-85. doi: 10.1038/nature18930

[13]	Zhao M, Yang M, Li X M, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(3): 755-760.

[14]	Felgner S, Frahm M, Kocijancic D, et al. aroA-deficient Salmonella enterica serovar typhimurium is more than a metabolically attenuated mutant. mBio, 2016, 7(5): e01220-16.

[15]	Leventhal D S, Sokolovska A, Li N, et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nature Communications, 2020, 11: 2739. doi: 10.1038/s41467-020-16602-0 pmid: 32483165

[16]	Yu B, Yang M, Shi L, et al. Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella typhimurium strain. Scientific Reports, 2012, 2(1): 1-10.

[17]	Bereta M, Hayhurst A, Gajda M, et al. Improving tumor targeting and therapeutic potential of Salmonella VNP 20009 by displaying cell surface CEA-specific antibodies. Vaccine, 2007, 25(21): 4183-4192. doi: 10.1016/j.vaccine.2007.03.008

[18]	Park S H, Zheng J H, Nguyen V H, et al. RGD peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated Salmonella-mediated cancer therapy. Theranostics, 2016, 6(10): 1672-1682. doi: 10.7150/thno.16135

[19]	Geng Z M, Cao Z P, Liu R, et al. Aptamer-assisted tumor localization of bacteria for enhanced biotherapy. Nature Communications, 2021, 12: 6584. doi: 10.1038/s41467-021-26956-8 pmid: 34782610

[20]	Clairmont C, Lee K C, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimuvium. The Journal of Infectious Diseases, 2000, 181(6): 1996-2002. doi: 10.1086/jid.2000.181.issue-6

[21]	Liang K, Liu Q, Li P, et al. Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models. Cancer Gene Therapy, 2018, 25(7): 167-183. doi: 10.1038/s41417-018-0021-6

[22]	Chiang C J, Hong Y H. In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy. Scientific Reports, 2021, 11: 18172. doi: 10.1038/s41598-021-97457-3

[23]	Chiang C J, Huang P H. Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors. Scientific Reports, 2021, 11: 5853. doi: 10.1038/s41598-021-85372-6

[24]	Friedlos F, Lehouritis P, Ogilvie L, et al. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clinical Cancer Research, 2008, 14: 4259-4266. doi: 10.1158/1078-0432.CCR-07-4800 pmid: 18594008

[25]	Cheng C M, Lu Y L, Chuang K H, et al. Tumor-targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Therapy, 2008, 15(6): 393-401. doi: 10.1038/cgt.2008.10 pmid: 18369382

[26]	Ho C L, Tan H Q, Chua K J, et al. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Nature Biomedical Engineering, 2018, 2(1): 27-37. doi: 10.1038/s41551-017-0181-y pmid: 31015663

[27]	He L, Yang H J, Liu F, et al. Escherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth. Oncotarget, 2017, 8(49): 85772-85782. doi: 10.18632/oncotarget.v8i49

[28]	Xie S Z, Zhao L, Song X J, et al. Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release. Journal of Controlled Release, 2017, 268: 390-399. doi: 10.1016/j.jconrel.2017.10.041

[29]	Zoaby N, Shainsky-Roitman J, Badarneh S, et al. Autonomous bacterial nanoswimmers target cancer. Journal of Controlled Release, 2017, 257: 68-75. doi: S0168-3659(16)30940-3 pmid: 27744036

[30]	Van Du Nguyen, Han J W, Choi Y J, et al. Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella typhimurium). Sensors and Actuators B: Chemical, 2016, 224: 217-224. doi: 10.1016/j.snb.2015.09.034

[31]	Yoon W, Park Y C, Kim J, et al. Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma. European Journal of Cancer, 2017, 70: 48-61. doi: 10.1016/j.ejca.2016.10.010

[32]	Loeffler M, Le’Negrate G, Krajewska M, et al. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(31): 12879-12883.

[33]	al-Ramadi B K, Fernandez-Cabezudo M J, El-Hasasna H, et al. Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clinical Immunology, 2009, 130(1): 89-97. doi: 10.1016/j.clim.2008.08.021 pmid: 18849195

[34]	Chowdhury S, Castro S, Coker C, et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nature Medicine, 2019, 25(7): 1057-1063. doi: 10.1038/s41591-019-0498-z pmid: 31270504

[35]	Gurbatri C R, Lia I, Vincent R, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Science Translational Medicine, 2020, 12(530): eaax0876. doi: 10.1126/scitranslmed.aax0876

[36]	Gao G Q, Ma T, Zhang T, et al. Adjunctive probiotic Lactobacillus rhamnosus probio-M9 administration enhances the effect of anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota. Frontiers in Immunology, 2021, 12: 772532. doi: 10.3389/fimmu.2021.772532

[37]	Selvanesan B C, Chandra D, Quispe-Tintaya W, et al. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Science Translational Medicine, 2022, 14(637): eabc1600. doi: 10.1126/scitranslmed.abc1600

[38]	Chen F M, Zang Z S, Chen Z, et al. Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy. Biomaterials, 2019, 214: 119226. doi: 10.1016/j.biomaterials.2019.119226

[39]	Fan J X, Li Z H, Liu X H, et al. Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration. Nano Letters, 2018, 18(4): 2373-2380. doi: 10.1021/acs.nanolett.7b05323

[40]	Chen W F, Guo Z F, Zhu Y N, et al. Combination of bacterial-photothermal therapy with an anti-PD-1 peptide depot for enhanced immunity against advanced cancer. Advanced Functional Materials, 2020, 30(1): 1906623. doi: 10.1002/adfm.v30.1

[41]	Li J J, Xia Q, Guo H Y, et al. Frontispiece:decorating bacteria with triple immune nanoactivators generates tumor-resident living immunotherapeutics. Angewandte Chemie International Edition, 2022, 61(27): e202282762.

[42]	Wang L, Cao Z P, Zhang M M, et al. Spatiotemporally controllable distribution of combination therapeutics in solid tumors by dually modified bacteria. Advanced Materials, 2022, 34(1): 2106669. doi: 10.1002/adma.v34.1

[43]	Liu L L, He H M, Luo Z Y, et al. In situ photocatalyzed oxygen generation with photosynthetic bacteria to enable robust immunogenic photodynamic therapy in triple-negative breast cancer. Advanced Functional Materials, 2020, 30(10): 1910176. doi: 10.1002/adfm.v30.10

[44]	Yan S Q, Zeng X M, Wang Y, et al. Biomineralization of bacteria by a metal-organic framework for therapeutic delivery. Advanced Healthcare Materials, 2020, 9(12): 2000046. doi: 10.1002/adhm.v9.12

[45]	Grozdanov L, Zähringer U, Blum-Oehler G, et al. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain nissle 1917. Journal of Bacteriology, 2002, 184(21): 5912-5925. doi: 10.1128/JB.184.21.5912-5925.2002 pmid: 12374825

[46]	Sturm A, Rilling K, Baumgart D C, et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infection and Immunity, 2005, 73(3): 1452-1465. doi: 10.1128/IAI.73.3.1452-1465.2005

[47]	Arribas B, Rodríguez-Cabezas M, Camuesco D, et al. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. British Journal of Pharmacology, 2009, 157(6): 1024-1033. doi: 10.1111/j.1476-5381.2009.00270.x pmid: 19486007

[48]	Chua K J, Kwok W C, Aggarwal N, et al. Designer probiotics for the prevention and treatment of human diseases. Current Opinion in Chemical Biology, 2017, 40: 8-16. doi: S1367-5931(17)30050-9 pmid: 28478369

[49]	Singh B, Mal G, Marotta F. Designer probiotics: paving the way to living therapeutics. Trends in Biotechnology, 2017, 35(8): 679-682. doi: S0167-7799(17)30082-3 pmid: 28483159

[50]	Shen H K, Zhao Z T, Zhao Z J, et al. Native and engineered probiotics: promising agents against related systemic and intestinal diseases. International Journal of Molecular Sciences, 2022, 23(2): 594. doi: 10.3390/ijms23020594

[51]	王彦雯, 叶静怡, 王鹏超. 合成生物学在E.coli Nissle 1917靶向治疗癌症中的应用. 中国生物化学与分子生物学报, 2021, 37(1): 20-28.

[51]	Wang Y W, Ye J Y, Wang P C. Application of synthetic biology in targeted cancer therapies by E.coli Nissle 1917. Chinese Journal of Biochemistry and Molecular Biology, 2021, 37(1): 20-28.

[52]	Fischbach M A, Bluestone J A, Lim W A. Cell-based therapeutics: the next pillar of medicine. Science Translational Medicine, 2013, 5(179): e3005568.

[53]	Weber W, Fussenegger M. Emerging biomedical applications of synthetic biology. Nature Reviews Genetics, 2012, 13(1): 21-35. doi: 10.1038/nrg3094

[54]	Wu M R, Jusiak B, Lu T K. Engineering advanced cancer therapies with synthetic biology. Nature Reviews Cancer, 2019, 19(4): 187-195.

[55]	Forbes N S. Engineering the perfect (bacterial) cancer therapy. Nature Reviews Cancer, 2010, 10(11): 785-794. doi: 10.1038/nrc2934 pmid: 20944664

[56]	Zhou S B, Gravekamp C, Bermudes D, et al. Tumour-targeting bacteria engineered to fight cancer. Nature Reviews Cancer, 2018, 18(12): 727-743. doi: 10.1038/s41568-018-0070-z pmid: 30405213

[57]	Piñero-Lambea C, Ruano-Gallego D, Fernández L Á. Engineered bacteria as therapeutic agents. Current Opinion in Biotechnology, 2015, 35: 94-102. doi: 10.1016/j.copbio.2015.05.004 pmid: 26070111

[58]	Pedrolli D B, Ribeiro N V, Squizato P N, et al. Engineering microbial living therapeutics: the synthetic biology toolbox. Trends in Biotechnology, 2019, 37(1): 100-115. doi: S0167-7799(18)30258-0 pmid: 30318171

[59]	Chien T, Doshi A, Danino T. Advances in bacterial cancer therapies using synthetic biology. Current Opinion in Systems Biology, 2017, 5: 1-8. doi: 10.1016/j.coisb.2017.05.009 pmid: 29881788

[60]	Wu F, Liu J Y. Decorated bacteria and the application in drug delivery. Advanced Drug Delivery Reviews, 2022, 188: 114443. doi: 10.1016/j.addr.2022.114443

[61]	Youn W, Kim J Y, Park J, et al. Single-cell nanoencapsulation: from passive to active shells. Advanced Materials, 2020, 32(35): 1907001. doi: 10.1002/adma.v32.35

[62]	Centurion F, Basit A W, Liu J Y, et al. Nanoencapsulation for probiotic delivery. ACS Nano, 2021, 15(12): 18653-18660. doi: 10.1021/acsnano.1c09951 pmid: 34860008

[63]	Niβle A. Weiteres über grundlagen und Praxis der mutaflorbehandlung. DMW - Deutsche Medizinische Wochenschrift, 1925, 51(44): 1809-1813. doi: 10.1055/s-0028-1137292

[64]	Ou B M, Yang Y, Tham W L, et al. Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application. Applied Microbiology and Biotechnology, 2016, 100(20): 8693-8699. doi: 10.1007/s00253-016-7829-5

[65]	Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, 53(11): 1617-1623. doi: 10.1136/gut.2003.037747 pmid: 15479682

[66]	Sonnenborn U. Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiology Letters, 2016, 363(19): fnw212. doi: 10.1093/femsle/fnw212

[67]	Wassenaar T M. Insights from 100 years of research with probiotic E. coli. European Journal of Microbiology and Immunology, 2016, 6(3): 147-161. pmid: 27766164

[68]	Reister M, Hoffmeier K, Krezdorn N, et al. Complete genome sequence of the Gram-negative probiotic Escherichia coli strain Nissle 1917. Journal of Biotechnology, 2014, 187: 106-107. doi: 10.1016/j.jbiotec.2014.07.442 pmid: 25093936

[69]	Sonnenborn U, Schulze J. The non-pathogenic Escherichia coli strain Nissle 1917-features of a versatile probiotic. Microbial Ecology in Health and Disease, 2009, 21(3-4): 122-158. doi: 10.3109/08910600903444267

[70]	Zhang Y L, Ji W, He L, et al. E. coli Nissle 1917-derived minicells for targeted delivery of chemotherapeutic drug to hypoxic regions for cancer therapy. Theranostics, 2018, 8(6): 1690-1705. doi: 10.7150/thno.21575

[71]	Zhang Y L, Zhang Y M, Xia L Q, et al. Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Applied and Environmental Microbiology, 2012, 78(21): 7603-7610. doi: 10.1128/AEM.01390-12

[72]	Yu X L, Lin C S, Yu J, et al. Bioengineered Escherichia coli Nissle 1917 for tumour-targeting therapy. Microbial Biotechnology, 2020, 13(3): 629-636. doi: 10.1111/mbt2.v13.3

[73]	Grozdanov L, Raasch C, Schulze J, et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. Journal of Bacteriology, 2004, 186(16): 5432-5441. doi: 10.1128/JB.186.16.5432-5441.2004 pmid: 15292145

[74]	Hacker J, Carniel E. Ecological fitness, genomic islands and bacterial pathogenicity. EMBO Reports, 2001, 2(5): 376-381. doi: 10.1093/embo-reports/kve097 pmid: 11375927

[75]	van der Hooft J J J, Goldstone R J, Harris S, et al. Substantial extracellular metabolic differences found between phylogenetically closely related probiotic and pathogenic strains of Escherichia coli. Frontiers in Microbiology, 2019, 10: 252. doi: 10.3389/fmicb.2019.00252

[76]	Behnsen J, Deriu E, Sassone-Corsi M, et al. Probiotics: properties, examples, and specific applications. Cold Spring Harbor Perspectives in Medicine, 2013, 3(3): a010074.

[77]	Hafez M, Hayes K, Goldrick M, et al. The K5 capsule of Escherichia coli strain nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. Infection and Immunity, 2009, 77(7): 2995-3003. doi: 10.1128/IAI.00040-09

[78]	Hafez M, Hayes K, Goldrick M, et al. The K5 capsule of Escherichia coli strain Nissle 1917 is important in stimulating expression of toll-like receptor 5, CD14, MyD88, and TRIF together with the induction of interleukin-8 expression via the mitogen-activated protein kinase pathway in epithelial cells. Infection and Immunity, 2010, 78(5): 2153-2162. doi: 10.1128/IAI.01406-09

[79]	Nzakizwanayo J, Kumar S, Ogilvie L A, et al. Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health. PLoS One, 2015, 10(3): e0120430. doi: 10.1371/journal.pone.0120430

[80]	Li R J, Helbig L, Fu J, et al. Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy. Research in Microbiology, 2019, 170(2): 74-79. doi: 10.1016/j.resmic.2018.11.001

[81]	Xie S Z, Chen M H, Song X J, et al. Bacterial microbots for acid-labile release of hybrid micelles to promote the synergistic antitumor efficacy. Acta Biomaterialia, 2018, 78: 198-210. doi: S1742-7061(18)30442-2 pmid: 30036720

[82]	Xie S Z, Zhang P, Zhang Z L, et al. Bacterial navigation for tumor targeting and photothermally-triggered bacterial ghost transformation for spatiotemporal drug release. Acta Biomaterialia, 2021, 131: 172-184. doi: 10.1016/j.actbio.2021.06.030 pmid: 34171461

[83]	Abedi M H, Yao M S, Mittelstein D R, et al. Ultrasound-controllable engineered bacteria for cancer immunotherapy. Nature Communications, 2022, 13: 1585. doi: 10.1038/s41467-022-29065-2 pmid: 35332124

[84]	Chen J H, Li X H, Liu Y M, et al. Engineering a probiotic strain of Escherichia coli to induce the regression of colorectal cancer through production of 5-aminolevulinic acid. Microbial Biotechnology, 2021, 14(5): 2130-2139. doi: 10.1111/mbt2.v14.5

[85]	Canale F P, Basso C, Antonini G, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature, 2021, 598(7882): 662-666. doi: 10.1038/s41586-021-04003-2

[86]	Huang C Y, Wang F B, Liu L, et al. Hypoxic tumor radiosensitization using engineered probiotics. Advanced Healthcare Materials, 2021, 10(10): 2002207. doi: 10.1002/adhm.v10.10

[87]	Geiger R, Rieckmann J C, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell, 2016, 167(3): 829-842.e13. doi: S0092-8674(16)31313-7 pmid: 27745970

[88]	张悦, 邢仕歌, 王震, 等. 核酸适配体在靶向药物传递中的研究进展. 生物化学与生物物理进展, 2015, 42(3): 236-243.

[88]	Zhang Y, Xing S G, Wang Z, et al. Recent research of aptamer in target drug delivery. China Industrial Economics, 2015, 42(3): 236-243.

[89]	Cao Z P, Cheng S S, Wang X Y, et al. Camouflaging bacteria by wrapping with cell membranes. Nature Communications, 2019, 10: 3452. doi: 10.1038/s41467-019-11390-8 pmid: 31388002

[90]	Feng P P, Cao Z P, Wang X Y, et al. On-demand bacterial reactivation by restraining within a triggerable nanocoating. Advanced Materials, 2020, 32(34): 2002406. doi: 10.1002/adma.v32.34

[91]	Liu Y, Zhang M M, Wang X Y, et al. Dressing bacteria with a hybrid immunoactive nanosurface to elicit dual anticancer and antiviral immunity. Advanced Materials, 2023, 35(11): 2210949. doi: 10.1002/adma.v35.11

[92]	林思思, 潘超, 张一帆, 等. 基于表面涂层益生菌的肿瘤抗原口服递送系统. 合成生物学, 2022(4): 810-820. doi: 10.12211/2096-8280.2022-010

[92]	Lin S S, Pan C, Zhang Y F, et al. Coated probiotic-based drug carriers for oral delivery of tumor antigens. Synthetic Biology Journal, 2022(4): 810-820. doi: 10.12211/2096-8280.2022-010

[93]	Lehouritis P, Stanton M, McCarthy F O, et al. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria. Journal of Controlled Release, 2016, 222: 9-17. doi: 10.1016/j.jconrel.2015.11.030 pmid: 26655063

[94]	Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Letters, 2012, 320(2): 130-137 doi: 10.1016/j.canlet.2012.03.008 pmid: 22425960

[95]	He L, Yang H J, Tang J L, et al. Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. Journal of Biological Engineering, 2019, 13(1): 1-13. doi: 10.1186/s13036-018-0125-4

[96]	Drummond D C, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacological Reviews, 1999, 51(4): 691-743. pmid: 10581328

[97]	Webb B A, Chimenti M, Jacobson M P, et al. Dysregulated pH: a perfect storm for cancer progression. Nature Reviews Cancer, 2011, 11(9): 671-677. doi: 10.1038/nrc3110 pmid: 21833026

[98]	Zhou J H, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nature Reviews Drug Discovery, 2017, 16(3): 181-202. doi: 10.1038/nrd.2016.199 pmid: 27807347

[99]	崔超, 涂强, 张友明. 细菌用于靶向治疗肿瘤的研究进展. 中国抗生素杂志, 2021, 46(5):388-395.

[99]	Cui C, Tu Q, Zhang Y M. Advances in bacteria for tumor-targeting therapy. Chinese Journal of Antibiotics, 2021, 46(5):388-395.

[100]	Wu L Y, Bao F F, Li L, et al. Bacterially mediated drug delivery and therapeutics: strategies and advancements. Advanced Drug Delivery Reviews, 2022, 187: 114363. doi: 10.1016/j.addr.2022.114363

[101]	Yang E, Qian W P, Cao Z H, et al. Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. Theranostics, 2015, 5(1): 43-61. doi: 10.7150/thno.10350 pmid: 25553097

[102]	Cheng T J, Liu J J, Ren J, et al. Green tea catechin-based complex micelles combined with doxorubicin to overcome cardiotoxicity and multidrug resistance. Theranostics, 2016, 6(9): 1277-1292. doi: 10.7150/thno.15133 pmid: 27375779

[103]	Postow M A, Callahan M K, Wolchok J D. Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology, 2015, 33(17): 1974-1982. doi: 10.1200/JCO.2014.59.4358 pmid: 25605845

[104]	Gerard C L, Delyon J, Wicky A, et al. Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews, 2021, 101: 102227. doi: 10.1016/j.ctrv.2021.102227

[105]	Appleton E, Hassan J, Chan Wah Hak C, et al. Kickstarting immunity in cold tumours: localised tumour therapy combinations with immune checkpoint blockade. Frontiers in Immunology, 2021, 12: 754436. doi: 10.3389/fimmu.2021.754436

[106]	Tang Q, Peng X, Xu B, et al. Current status and future directions of bacteria-based immunotherapy. Frontiers in Immunology, 2022, 13: 911783. doi: 10.3389/fimmu.2022.911783

[107]	Ribas A, Wolchok J D. Cancer immunotherapy using checkpoint blockade. Science, 2018, 359(6382): 1350-1355. doi: 10.1126/science.aar4060 pmid: 29567705

[108]	Gu J, Wu A W, Li J Y, et al. An assessment of World Health Organization criteria for severe acute respiratory syndrome in patients with cancer. Cancer, 2004, 100(7): 1374-1378. pmid: 15042670

[109]	Corrales L, Glickman L H, McWhirter S M, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Reports, 2015, 11(7): 1018-1030. doi: 10.1016/j.celrep.2015.04.031 pmid: 25959818

[110]	Lin M J, Svensson-Arvelund J, Lubitz G S, et al. Cancer vaccines: the next immunotherapy frontier. Nature Cancer, 2022, 3(8): 911-926. doi: 10.1038/s43018-022-00418-6 pmid: 35999309

[111]	Zhen X, Cheng P H, Pu K Y. Recent advances in cell membrane-camouflaged nanoparticles for cancer phototherapy. Small, 2019, 15(1): 1804105. doi: 10.1002/smll.v15.1

[112]	郭弘, 李霞, 瞿鼎, 等. Fe基金属-有机框架在抗肿瘤药物递送方面的研究进展. 药学学报, 2022, 57(5): 1252-1262.

[112]	Guo H, Li X, Qu D, et al. Research progress on Fe-based metal-organic frameworks in antitumor drug delivery. Acta Pharmaceutica Sinica, 2022, 57(5): 1252-1262.

[113]	Lin D W, Feng X L, Mai B J, et al. Bacterial-based cancer therapy: an emerging toolbox for targeted drug/gene delivery. Biomaterials, 2021, 277: 121124. doi: 10.1016/j.biomaterials.2021.121124

[114]	Zhang N, Song J, Liu Y, et al. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. Journal of Controlled Release, 2019, 306: 15-28. doi: S0168-3659(19)30300-1 pmid: 31132380

[115]	Luo L H, Zhu C Q, Yin H, et al. Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors. ACS Nano, 2018, 12(8): 7647-7662. doi: 10.1021/acsnano.8b00204 pmid: 30020768

[116]	Dougherty T J, Gomer C J, Henderson B W, et al. Photodynamic therapy. JNCI: Journal of the National Cancer Institute, 1998, 90(12): 889-905. doi: 10.1093/jnci/90.12.889

[1]	HAN Jia, FAN Yue-lei, MAO Kai-yun. Analysis of Oncolytic Virus Market and R&D Pattern[J]. China Biotechnology, 2023, 43(6): 87-101.

[2]	SU Ling-yu, ZOU Jin-tao, NIU An-na, ZHANG Wei, ZHANG Xiao-peng, CHEN Wei. Anti-tumor Effect of CAR-NK Cells Targeting Prostate Cancer[J]. China Biotechnology, 2023, 43(6): 1-11.

[3]	FU Meng-meng, SU Dan-dan, ZUO Kun-lan, WU Zong-zhen, LI Si-si, XU Yan-long, LIU Huan. Biosafety Risks of Synthetic Biology Related to Human Immunity and The Countermeaseures[J]. China Biotechnology, 2023, 43(6): 125-132.

[4]	LIU Ting-ting, ZHANG Ping, ZHANG Yue. Regulation Role of Light-controlled Expression Systems in Synthetic Biology[J]. China Biotechnology, 2023, 43(4): 92-100.

[5]	ZHANG Xin, ZHANG Rui, TANG Jing-feng. Functional Studies of AMOT Family Members and Their Potential Applications in Cancer Therapy[J]. China Biotechnology, 2023, 43(2/3): 104-119.

[6]	NING Jun-tao, ZOU Shi-shi, ZUO Kun-lan, WU Zong-zhen, Li Jing, XU Yan-long, LIU Huan. Biosafety Risks and Countermeasures of Active Substance in Synthesis Biology[J]. China Biotechnology, 2023, 43(2/3): 180-189.

[7]	YANG Yang, YAO Ming-dong, WANG Ying, XIAO Wen-hai. Research Progress of Synthesis of 2'-Fucosyllactose by Yeast[J]. China Biotechnology, 2023, 43(1): 127-138.

[8]	DENG Si-yu, LIANG Bing, WEI Wei, WANG Meng-na, CAO You-de. Effects of miR-34a-5p on Triple Negative Breast Cancer Cells and Related Mechanisms[J]. China Biotechnology, 2023, 43(1): 18-26.

[9]	LIANG Fan,CHENG Hong-wei,ZHANG Jun-he. Establishment and Application Progress of Patient-derived Xenograft Model of Esophageal Cancer[J]. China Biotechnology, 2022, 42(8): 74-84.

[10]	Zhi-xin YAO,Wan-ming LI. Advances in Aptamers in the Diagnosis and Treatment of Triple-negative Breast Cancer[J]. China Biotechnology, 2022, 42(7): 62-68.

[11]	Xue-xia ZENG,Yu DAN,Shao-ming MAO,Jia-hui SUN,Guo-dong LUAN,Xue-feng LV. Research Progress on the Cyanobacterial Photosynthetic Production of Sugars Utilizing Carbon Dioxide[J]. China Biotechnology, 2022, 42(7): 90-100.

[12]	ZHANG Da-lu,GE Qi,FENG Yi-bo,CHEN Wei-gang. Comparison and Analysis on Scientific Research Programs on DNA Data Storage[J]. China Biotechnology, 2022, 42(6): 116-129.

[13]	BAI Song,HOU Zheng-jie,GAO Geng-rong,QIAO Bin,CHENG Jing-sheng. Advances in the Synthesis of Odd-chain Fatty Acids by Microorganisms[J]. China Biotechnology, 2022, 42(6): 76-85.

[14]	YUAN Shu-hui,LI Shao-hua,FANG Wei,PENG Zhi-qiang,ZHANG Ling-qiang. XIAP Mediated-PTEN Neddylation Promotes Proliferation and Migration of Colon Cancer Cells[J]. China Biotechnology, 2022, 42(5): 27-36.

[15]	BAO Yi-kai,HONG Hao-fei,SHI Jie,ZHOU Zhi-fang,WU Zhi-meng. Development and Biological Activity Analysis of PSMA Specific Mutivalent Nanobodies[J]. China Biotechnology, 2022, 42(5): 37-45.

Viewed

Full text

Abstract

Cited

Shared

Discussed